Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$23.0 - $31.04 $5.81 Million - $7.85 Million
252,793 New
252,793 $6.4 Million
Q4 2023

Feb 14, 2024

SELL
$24.02 - $43.89 $4.25 Million - $7.77 Million
-177,099 Reduced 68.88%
79,999 $3.23 Million
Q2 2023

Aug 14, 2023

BUY
$13.29 - $18.01 $126,653 - $171,635
9,530 Added 3.85%
257,098 $4.42 Million
Q1 2023

May 15, 2023

BUY
$7.17 - $18.55 $1.51 Million - $3.91 Million
210,814 Added 573.58%
247,568 $4.1 Million
Q4 2022

Feb 14, 2023

SELL
$6.74 - $11.52 $1.68 Million - $2.87 Million
-248,912 Reduced 87.13%
36,754 $280,000
Q3 2022

Nov 14, 2022

BUY
$7.94 - $12.36 $1.32 Million - $2.05 Million
165,973 Added 138.67%
285,666 $2.84 Million
Q2 2022

Aug 15, 2022

SELL
$5.21 - $12.14 $122,377 - $285,156
-23,489 Reduced 16.4%
119,693 $1.09 Million
Q1 2022

May 16, 2022

BUY
$7.34 - $17.16 $401,578 - $938,840
54,711 Added 61.84%
143,182 $1.45 Million
Q4 2021

Feb 14, 2022

BUY
$11.38 - $53.41 $499,536 - $2.34 Million
43,896 Added 98.48%
88,471 $1.48 Million
Q3 2021

Nov 15, 2021

BUY
$46.87 - $64.24 $126,174 - $172,934
2,692 Added 6.43%
44,575 $2.09 Million
Q2 2021

Aug 16, 2021

BUY
$46.47 - $63.93 $918,014 - $1.26 Million
19,755 Added 89.28%
41,883 $2.55 Million
Q1 2021

May 17, 2021

BUY
$55.47 - $72.35 $100,178 - $130,664
1,806 Added 8.89%
22,128 $1.36 Million
Q4 2020

Feb 16, 2021

BUY
$38.38 - $71.11 $181,422 - $336,136
4,727 Added 30.31%
20,322 $1.45 Million
Q3 2020

Nov 16, 2020

SELL
$27.2 - $42.19 $47,355 - $73,452
-1,741 Reduced 10.04%
15,595 $585,000
Q2 2020

Aug 14, 2020

BUY
$22.22 - $35.69 $385,205 - $618,721
17,336 New
17,336 $565,000

Others Institutions Holding BBIO

About BridgeBio Pharma, Inc.


  • Ticker BBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 148,246,000
  • Market Cap $4.23B
  • Description
  • BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...
More about BBIO
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.